Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 3, 2014, Pages 648-658

  Chen, Wen Hsiang ^a   Du, Lanying ^b   Chag, Shivali M ^a   Ma, Cuiqing ^b   Tricoche, Nancy ^b   Tao, Xinrong ^c   Seid, Christopher A ^a   Hudspeth, Elissa M ^a   Lustigman, Sara ^b   Tseng, Chien Te K ^c   Bottazzi, Maria Elena ^a   Hotez, Peter J ^a   Zhan, Bin ^a   Jiang, Shibo ^b,d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NEW YORK BLOOD CENTER   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

^d FUDAN UNIVERSITY   (China)

Author keywords

Deglycosylation; Receptor binding domain; SARS CoV; Vaccine; Yeast expression

Indexed keywords

ALUMINUM POTASSIUM SULFATE; NEUTRALIZING ANTIBODY; PROTEIN RBD193; PROTEIN RBD219; RECOMBINANT PROTEIN; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; UNCLASSIFIED DRUG; VIRUS SPIKE PROTEIN; ALUMINUM SULFATE; CORONAVIRUS SPIKE GLYCOPROTEIN; IMMUNOLOGICAL ADJUVANT; RECOMBINANT VACCINE; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; DEGLYCOSYLATION; FEMALE; IMMUNOGENICITY; MOUSE; NONHUMAN; PICHIA PASTORIS; PROTEIN EXPRESSION; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; ANIMAL; BAGG ALBINO MOUSE; GENE EXPRESSION; GENETICS; GLYCOSYLATION; IMMUNOLOGY; PICHIA;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; FEMALE; GENE EXPRESSION; GLYCOSYLATION; MICE, INBRED BALB C; PICHIA; RECOMBINANT PROTEINS; SARS VIRUS; SPIKE GLYCOPROTEIN, CORONAVIRUS; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 84898409678     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.27464     Document Type: Article

References (32)

1. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV - a target for vaccine and therapeutic development. Nat Rev Microbiol 2009; 7:226-36; PMID:19198616; http://dx.doi.org/10.1038/nrmicro2090
2. Peiris JSM, Lai ST, Poon LLM, Guan Y, Yam LY, Lim W, Nicholls J, Yee WK, Yan WW, Cheung MT, et al.; SARS study group. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361:1319-25; PMID:12711465; http://dx.doi.org/10.1016/S0140-6736(03)13077-2
3. Zhong NS, Zheng BJ, Li YM, Poon, Xie ZH, Chan KH, Li PH, Tan SY, Chang Q, Xie JP, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet 2003; 362:1353-8; PMID:14585636; http://dx.doi.org/10.1016/S0140-6736(03)14630-2
4. Jiang S, Bottazzi ME, Du L, Lustigman S, Tseng CT, Curti E, Jones K, Zhan B, Hotez PJ. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines 2012; 11:1405-13; PMID:23252385; http://dx.doi.org/10.1586/erv.12. 126
5. Perlman S, Dandekar AA. Immunopathogenesis of coronavirus infections: implications for SARS. Nat Rev Immunol 2005; 5:917-27; PMID:16322745; http://dx.doi.org/10.1038/nri1732
6. Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, Funkhouser W, Gralinski L, Totura A, Heise M, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol 2011; 85:12201-15; PMID:21937658; http://dx.doi.org/10. 1128/JVI.06048-11
7. Castilow EM, Olson MR, Varga SM. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol Res 2007; 39:225-39; PMID:17917067; http://dx.doi.org/10.1007/s12026-007-0071-6
8. Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, Peters CJ, Couch RB. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One 2012; 7:e35421; PMID:22536382; http://dx.doi.org/10.1371/journal.pone.0035421
9. Jaume M, Yip MS, Kam YW, Cheung CY, Kien F, Roberts A, Li PH, Dutry I, Escriou N, Daeron M, et al. SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement. Hong Kong Med J 2012; 18(Suppl 2):31-6; PMID:22311359
10. Wong SK, Li W, Moore MJ, Choe H, Farzan M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem 2004; 279:3197-201; PMID:14670965; http://dx.doi.org/10.1074/jbc. C300520200
11. Du L, Zhao G, Chan CC, Sun S, Chen M, Liu Z, Guo H, He Y, Zhou Y, Zheng BJ, et al. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology 2009; 393:144-50; PMID:19683779; http://dx.doi.org/10.1016/j.virol.2009.07.018
12. Du L, Zhao G, Chan CC, Li L, He Y, Zhou Y, Zheng BJ, Jiang S. A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity. Viral Immunol 2010; 23:211-9; PMID:20374001; http://dx.doi.org/10.1089/vim.2009.0090
13. Chen Z, Zhang L, Qin C, Ba L, Yi CE, Zhang F, Wei Q, He T, Yu W, Yu J, et al. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol 2005; 79:2678-88; PMID:15708987; http://dx.doi.org/10.1128/JVI.79.5.2678- 2688.2005
14. He Y, Lu H, Siddiqui P, Zhou Y, Jiang S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 2005; 174:4908-15; PMID:15814718
15. Du L, Zhao G, Li L, He Y, Zhou Y, Zheng BJ, Jiang S. Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells. Biochem Biophys Res Commun 2009; 384:486-90; PMID:19422787; http://dx.doi.org/10.1016/j.bbrc.2009.05.003
16. Goud GN, Zhan B, Ghosh K, Loukas A, Hawdon J, Dobardzic A, Deumic V, Liu S, Dobardzic R, Zook BC, et al. Cloning, yeast expression, isolation, and vaccine testing of recombinant Ancylostoma-secreted protein (ASP)-1 and ASP-2 from Ancylostoma ceylanicum. J Infect Dis 2004; 189:919-29; PMID:14976610; http://dx.doi.org/10.1086/381901
17. Du L, Zhao G, Kou Z, Ma C, Sun S, Poon VK, Lu L, Wang L, Debnath AK, Zheng BJ, et al. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol 2013; 87:9939-42; PMID:23824801; http://dx.doi.org/10.1128/JVI.01048-13
18. Du L, Zhao G, Sun S, Zhang X, Zhou X, Guo Y, Li Y, Zhou Y, Jiang S. A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection. PLoS One 2013; 8:e53568; PMID:23320093; http://dx.doi.org/10.1371/journal.pone.0053568
19. Du L, Leung VH, Zhang X, Zhou J, Chen M, He W, Zhang HY, Chan CC, Poon VK, Zhao G, et al. A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses. PLoS One 2011; 6:e16555; PMID:21304591; http://dx.doi.org/10.1371/journal.pone. 0016555
20. Du L, Zhao G, Lin Y, Sui H, Chan C, Ma S, He Y, Jiang S, Wu C, Yuen KY, et al. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARSCoV infection. J Immunol 2008; 180:948-56; PMID:18178835
21. Du L, Zhao G, Lin Y, Chan C, He Y, Jiang S, Wu C, Jin DY, Yuen KY, Zhou Y, et al. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. Vaccine 2008; 26:1644-51; PMID:18289745; http://dx.doi.org/10.1016/j.vaccine.2008.01.025
22. He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M, Jiang S. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun 2004; 324:773-81; PMID:15474494; http://dx.doi.org/10.1016/j.bbrc.2004.09.106
23. He Y, Zhu Q, Liu S, Zhou Y, Yang B, Li J, Jiang S. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. Virology 2005; 334:74-82; PMID:15749124; http://dx.doi.org/10.1016/j.virol.2005.01.034
24. He Y, Li J, Li W, Lustigman S, Farzan M, Jiang S. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J Immunol 2006; 176:6085-92;.
25. Punt PJ, van Biezen N, Conesa A, Albers A, Mangnus J, van den Hondel C. Filamentous fungi as cell factories for heterologous protein production. Trends Biotechnol 2002; 20:200-6; PMID:11943375; http://dx.doi.org/10.1016/S0167- 7799(02)01933-9
26. Dean N. Asparagine-linked glycosylation in the yeast Golgi. Biochim Biophys Acta 1999; 1426:309-22; PMID:9878803; http://dx.doi.org/10.1016/S0304- 4165(98)00132-9
27. Shibata N, Ichikawa T, Tojo M, Takahashi M, Ito N, Okubo Y, Suzuki S. Immunochemical study on the mannans of Candida albicans NIH A-207, NIH B-792, and J-1012 strains prepared by fractional precipitation with cetyltrimethylammonium bromide. Arch Biochem Biophys 1985; 243:338-48; PMID:3002275; http://dx.doi.org/10.1016/0003-9861(85)90511-9
28. Hopkins D, Gomathinayagam S, Rittenhour AM, Du M, Hoyt E, Karaveg K, Mitchell T, Nett JH, Sharkey NJ, Stadheim TA, et al. Elimination of β-mannose glycan structures in Pichia pastoris. Glycobiology 2011; 21:1616-26; PMID:21840970; http://dx.doi.org/10.1093/glycob/cwr108
29. Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 2005; 309:1864-8; PMID:16166518; http://dx.doi.org/10.1126/science.1116480
30. Prabakaran P, Gan J, Feng Y, Zhu Z, Choudhry V, Xiao X, Ji X, Dimitrov DS. Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J Biol Chem 2006; 281:15829-36; PMID:16597622; http://dx.doi.org/10.1074/jbc.M600697200
31. Zakhartchouk AN, Sharon C, Satkunarajah M, Auperin T, Viswanathan S, Mutwiri G, Petric M, See RH, Brunham RC, Finlay BB, et al. Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine. Vaccine 2007; 25:136-43; PMID:16919855; http://dx.doi.org/10.1016/j.vaccine.2006.06.084
32. Trujillo JD, Kumpula-McWhirter NM, Hötzel KJ, Gonzalez M, Cheevers WP. Glycosylation of immunodominant linear epitopes in the carboxyterminal region of the caprine arthritis-encephalitis virus surface envelope enhances vaccine-induced type-specific and cross-reactive neutralizing antibody responses. J Virol 2004; 78:9190-202; PMID:15308714; http://dx.doi.org/10.1128/ JVI.78.17.9190-9202.2004